Literature DB >> 2596494

Plasma volume in resistant hypertension: guide to pathophysiology and therapy.

J W Graves1, R L Bloomfield, V M Buckalew.   

Abstract

It might be expected that the tremendous increase in available antihypertensives would eliminate resistant hypertension by allowing many alternatives to its treatment. In spite of this, resistant hypertension remains a common problem due, the authors feel, to a poor understanding of the pathophysiology of this condition, particularly an understanding of whether plasma volume expansion mediates resistance to antihypertensive therapy. The authors evaluated the status of plasma volume as a major determinant of response to therapy in nine patients with resistant hypertension. Measuring plasma volume using I125 radiolabeled albumin, they found eight patients with elevated plasma volumes and one patient with a contracted plasma volume at the time of presentation with resistant hypertension. In all eight patients with plasma volume expansion, aggressive diuretic therapy allowed goal blood pressure to be achieved. The patient with plasma volume contraction achieved goal blood pressure with vasodilator therapy. Plasma volume expansion is common in resistant hypertension and it mediates resistance to therapy. Measurement of plasma volume gives the clinician important insight into the pathophysiology of resistant hypertension and increases the likelihood of successful management of the resistant hypertensive patient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2596494     DOI: 10.1097/00000441-198912000-00001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  15 in total

Review 1.  Resistant hypertension and the Birmingham Hypertension Square.

Authors:  D C Felmeden; G Y Lip
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 2.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 3.  Should chlorthalidone be the diuretic of choice for antihypertensive therapy?

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

Review 4.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

5.  Predictors of resistant hypertension in an unselected sample of an adult male population in Italy.

Authors:  Antonio Barbato; Ferruccio Galletti; Roberto Iacone; Francesco P Cappuccio; Giovanni Rossi; Renato Ippolito; Antonella Venezia; Eduardo Farinaro; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2011-03-10       Impact factor: 3.397

Review 6.  Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

7.  Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program.

Authors:  F Galletti; A Barbato
Journal:  J Hum Hypertens       Date:  2016-03-03       Impact factor: 3.012

8.  Nocturnal blood pressure profiles among normotensive, controlled hypertensive and refractory hypertensive subjects.

Authors:  Oded Friedman; Alexander G Logan
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

Review 9.  Epidemiology of resistant hypertension.

Authors:  Pantelis A Sarafidis
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-03-28       Impact factor: 3.738

10.  Evaluation and treatment of resistant or difficult-to-control hypertension.

Authors:  David Wojciechowski; Vasilios Papademetriou; Charles Faselis; Ross Fletcher
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.